Biotech China 2014

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2011 COX-2 inhibition does not add to the anti-proliferative effect of exemestane in ductal carcinoma in situ: Results of the ERISAC randomised placebo controlled trial in postmenopausal women Clinical Cancer Research 2011; in press
2. 2011 Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole European Journal of Clinical Oncology 2011; in press
3. 2011 Breast infection Breast Surgical Techniques and Interdisciplinary Management Eds: Dirbas F, Scott-Conner CEH. Springer, New York, 2011; in press
4. 2011 The breast General Surgery: Principles and International Practice Eds: Bland K, Buechler M, Csendes A, Garden O, Sarr M, Wong J. Springer, London 2011; in press
5. 2011 The breast Surgery in Breast Cancer and Malignancy Eds: Bland K, Buechler M, Csendes A, Garden O, Sarr M, Wong J. Springer, London 2011; in press
6. 2011 Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability Breast Cancer Research and Treatment 2011; 125: 741-749
7. 2011 Steroid receptor coactivator-1 and Peroxisome-proliferator activated receptor γ coactivator-1α increase in breast cancer responsive to aromatase inhibitors Cancer Research 2011; in press
8. 2011 The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study Breast Cancer Research and Treatment 2011; in press. Published online: DOI 10.1007/s10549-010-0967-z
9. 2011 Implant-based augmentation mammaplasty following breast conservation surgery Implant-based augmentation mammaplasty following breast conservation surgery
10. 2010 Correcting for intra-experiment variation in illumine BeadChip data is necessary to generate robust gene-expression profiles BMC Genomics 2010; 11: 134
11. 2010 Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy European Journal of Cancer 2010; 46(18): 3219-3232.
12. 2010 Combining and sequencing adjuvant chemotherapy and tamoxifen in postmenopausal women with node positive breast cancer Women’s Health 2010; 6(3): 357-360
13. 2010 Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situe proliferation with aromatase inhibitor therapy: results of the ERISAC randomised placebo controlled trial Clinical Cancer Research 2010; 16(5): 1605-1612
14. 2010 Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer Breast Cancer Research and Treatment 2010; 120(2): 461-467
15. 2010 Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors Cancer Research 2010; 70(1): 319-328
16. 2010 So you want to be a breast surgeon British Journal of Hospital Medicine 2010; 71(1): M16
17. 2010 BIG 1-98 heralds new era of endocrine therapy for postmenopausal hormone receptor-positive early breast cancer Medicine Matters 2010; 162: 1
18. 2010 A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor positive breast cancer Breast Cancer Research and Treatment 2010; 119(3): 643
19. 2010 Combining and sequencing adjuvant chemotherapy and tamoxifen in postmenopausal women with node-positive breast cancer Women’s Health 2010; 6: 357-60
20. 2010 Role of sentinel node biopsy in patients having neoadjuvant chemotherapy European Journal of Surgical Oncology 2010; 36: 511-513
21. 2010 Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles BMC Genomics 2010; 11: 143
22. 2010 Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole The Pharmacogenomics Journal 2010; 1-12
23. 2010 A further survey of surgical management of the axilla in UK breast cancer patients. Annals of the Royal College of Surgeons of England 2010; 92: 506-511
24. 2010 Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer Breast Cancer Research 2010; 12: R39
25. 2010 Controversies in breast surgery. Annals of Surgical Oncology 2010; 17: S230-S232
26. 2010 Gene expression profiling of response to mTOR inhibitor Everolimus in preoperatively treated postmenopausal women with estrogen receptor positive breast cancer Breast Cancer Research and Treatment 2010; 122(2): 419-428
27. 2010 Chronic abscess formation following mesh mastopexy: case report Journal of Plastic, Aesthetic and Reconstructive Surgery, 2010; 63(7): 1220-1222
28. 2010 The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers Oncogene 2010; 29(34): 4838-4847
29. 2009 Neoadjuvant endocrine therapy. Kuerer’s Breast Surgical Oncology Ed: Kuerer HM. McGraw Hill Medical, New York, 2010, pp.877-884
30. 2009 Nuclear receptor coactivators and HER-2/neu are upregulated in breast cancer patients during neoadjuvant treatment with aromatase inhibitor British Journal of Cancer 2009; 101(8): 1253-1260
31. 2009 Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management Journal of Clinical Oncology 2009; 27(33): 5640-5649
32. 2009 Management of disorders of the ductal system and infections Diseases of the Breast, 3rd Edition. Eds: Harris JR, Lippman ME, Morrow M, Osborne CK. Lippincott Williams & Wilkins, Philadelphia, 2009, pp. 42-51
33. 2009 Breast-conserving surgery: the balance between good cosmesis and local control A Companion to Specialist Surgical Practice: Breast Surgery Ed: Dixon JM Elsevier, Edinburgh, 2009, pp. 49-65
34. 2009 Surgical treatment Current Innovations in the Treatment and Prevention of Breast Cancer. Ed: Rayter Z Royal Society of Medicine Press, London, 2009, pp.29-35
35. 2009 Increase in response rate by prolonged treatment with neoadjuvant letrozole Breast Cancer Research and Treatment 2009; 113: 145-151.
36. 2009 Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment 2009; 114: 211-221.
37. 2009 Adjuvant endocrine therapy for perimenopausal women with early breast cancer The Breast 2009; 18: 2-7
38. 2009 Effectiveness of immediate preoperative injection of radiopharmaceuticals and blue dye for sentinel node biopsy in patients with breast cancer European Journal of Cancer 2009; 45: 795-799
39. 2009 A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast Cancer Research and Treatment 2009; 114: 495-501
40. 2009 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features PNAS 2009; 106 (33): 13820-13825
41. 2009 Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole Journal of Clinical Oncology 2009; 27(9): 1382-1387
42. 2009 Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk Annals of Oncology 2009; 20: 816-827
43. 2009 Phase II randomized neoadjuvant study of the mTOR inhibitor everolimus (RAD001) in combination with letrozole versus placebo and letrozole in patients with ER+ breast cancer Journal of Clinical Oncology 2009; 27(16): 2630-2637
44. 2009 Breast screening has increased the number of mastectomies Breast Cancer Research 2009; 11(Suppl 3): S19
45. 2008 Breast cancer risk reduction and membrane-bound catechol o-methyltransferase genetic polymorphisms Cancer Research 2008; 68(14): 5997-6005
46. 2008 Breast carcinoma: stages I and II General Surgery. 2nd Edition. Eds: Bland KI, Buchler MW, Csendes A, Garden OJ, Sarr MG, Wong M. Springer, London, 2009, pp.1523-1540
47. 2008 Clinical studies with letrozole Aromatase Inhibitors. 2nd Edition. Ed: Furr BA. Birkhauser, Basel, 2008, pp 69-100
48. 2008 Follow-up after breast cancer BMJ 2008; 336: 107-108
49. 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. Journal of Clinical Oncology 2008; 26(10): 1671-1676
50. 2008 Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors Women’s Health 2008; 4(3): 229-231
51. 2008 Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer Expert Review of Anticancer Therapy 2008; 8(3); 453-463
52. 2008 Breast Problems Pulse, 2008; 14th May: 32-33
53. 2008 Accuracy and surgical impact of MRI in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer Journal of Clinical Oncology 2008; 26(19): 3248-3258
54. 2008 Predictors of mastectomy in a certified breast center – the surgeon is an independent risk factor. The Breast Journal 2008; 14(4): 321-323
55. 2008 Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence? The Breast 2008; 17: 353-360
56. 2008 Use of enoxaparin results in more haemorrhagic complications after breast surgery than unfractionated heparin British Journal of Surgery 2008; 95: 834-836
57. 2008 A pilot study of compositional analysis of the breast cancer estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imaging Cancer Epidemiology Biomarkers & Prevention 2008; 17: 2268-2274
58. 2008 Effects of switching from one nonsteroidal aromatase inhibitor to another in a postmenopausal patient with hormone-sensitive breast cancer: a case study American Journal of Hematology/Oncology 2008; 7(9): 381-387
59. 2008 What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy. Breast Cancer Research 2008; 10(4): S2
60. 2008 Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for Breast Cancer Research 2008; 10(4): S7
61. 2008 Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. Cancer 2008; 1(112): 689-694
62. 2008 Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer European Journal of Cancer 2008; 44: 391-399
63. 2007 For the use of ultrasound by surgeons Breast Cancer Online 2007; 10(3): 1-3
64. 2007 Hormone replacement therapy Menopause Digest 2007
65. 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer Journal of the National Cancer Institute 2007; 99(2): 167-170
66. 2007 Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor letrozole Pharmacogenetics and Genomics 2007; 17(10): 813-826
67. 2007 A luminal breast cancer genome atlas: progress and barriers Journal of Steroid Biochemistry & Molecular Pathology 2007; 106: 125-129
68. 2007 TELEMAM: A cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making European Journal of Cancer 2007; 43; 2506-2514
69. 2007 Does presurgical treatment destroy important prognostic information? Breast Cancer Research 2007; 9 (suppl 2): S17
70. 2007 The Breast Principles and Practice of Surgery Eds: Garden OJ, Bradbury AW, Forsythe JRL, Parks RW. Churchill Livingstone Elsevier, Edinburgh, 2007, pp 365-389
71. 2007 DCIS and aromatase inhibitors Journal of Steroid Biochemistry & Molecular Biology 2007; 106: 173-179
72. 2007 Molecular response to aromatase inhibitor treatment in primary breast cancer Breast Cancer Research 2007; 9: R37
73. 2007 Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology 2007; 51: 219-226
74. 2007 Breast abscess British Journal of Hospital Medicine 2007; 68: 315-320
75. 2007 Changing pattern of the detection of locorergional relapse in breast cancer: the Edinburgh experience British Journal of Cancer 2007; 96: 1802-1807.
76. 2007 A review of current practices in breast conservation surgery in the UK Annals of the Royal College of Surgeons of England 2007; 89(2): 118-123.
77. 2007 Neoadjuvant use of endocrine therapy in breast cancer The Breast 2007; 13(3): 243-250
78. 2006 Aromatase inhibitors in early breast cancer: a variety of treatment strategies Expert Opinion in Pharmacotherapy 2006; 7 (18): 2465-2479
79. 2006 Diagnosis and management of benign breast disease in older women Geriatrics and Aging 2006; 9 (9): 600-606
80. 2006 Cost effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at high familial risk of breast cancer British Journal of Cancer 2006; 95: 801-810
81. 2006 Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole Journal of Clinical Oncology 2006; 24 (19): 3019-3025
82. 2006 Extended adjuvant therapy with letrozole: reducing the risk of recurrence Expert Review of Anticancer Therapy 2006; 6 (6): 849-859
83. 2006 Oestrogen receptor β and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment British Journal of Cancer 2006; 94: 1333-1338
84. 2006 Breast conserving surgery Mastery of Surgery Eds: Fischer JE, Bland KI, Callery MP, Clagett GP, Jones DB, LoGerfo FW, Seeger JM. Lippincott Williams & Wilkins, Philadelphia, 2007, pp 502-516
85. 2006 Neoadjuvant breast cancer: hormone therapy Anti-Aromatase Therapy for Breast Cancer – New Developments. Eds: Sasano K, Toi M. Medical Science Publication Inc, Tokyo, 2006
86. 2006 Aromatase inhibitors in the adjuvant and extended adjuvant breast cancer settings: a review of new data. The Association of Breast Surgery at BASO Yearbook Ed: Sibbering M. BASO, London, 2006, pp 28-32.
87. 2006 Benign breast disease A Companion to Specialist Surgical Practice: Volume 5: Breast Disease, 3rd Edition Volume Ed: Dixon JM. Elsevier Ltd., Edinburgh 2006, pp 251-268
88. 2006 Breast conserving surgery: the balance between good cosmesis and local control A Companion to Specialist Surgical Practice: Volume 5: Breast Disease, 3rd Edition Volume Ed: Dixon JM. Elsevier Ltd., Edinburgh 2006, pp 47-64
89. 2006 Screening for breast cancer BMJ 2006; 332: 499-500
90. 2006 Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies European Journal of Surgical Oncology 2006; 32: 123-125
91. 2006 The prevention, detection and management of breast can Medical Journal of Australia 2006; 184 (5): 230-234
92. 2006 Surgeons’ views on multi-disciplinary breast meetings European Journal of Cancer 2006; 42: 905-908
93. 2006 Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase Breast Cancer Research and Treatment 2006; 99: 203-208
94. 2006 Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clinical Cancer Research 2006; 12 (3): 1024s-1030s
95. 2006 Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer Breast Cancer Research and Treatment 2006; 95(3): 279-293
96. 2006 Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial Journal of the National Cancer Institute 2006; 98(9): 599-609
97. 2006 Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer The Oncologist 2006; 11(10): 1081-1088
98. 2006 Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures International Journal of Oncology 2006; 29(6): 1581-1589
99. 2006 Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole British Journal of Cancer 2006; 94: 1051-1056
100. 2006 Group dynamics within telemedicine delivered and standard multidisciplinary team meetings: results from the TELEMAM randomised trial Journal of Telemedicine and Telecare 2006; 12 (suppl 3): 55-58.
101. 2005 Breast cancer (non-metastatic). Clinical Evidence Concise Ed: Onwude J. BMJ Publishing Group, London, 2005 (14), pp 555-560
102. 2005 Breast reconstruction ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 100-106.
103. 2005 Metastatic breast cancer ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 70-76.
104. 2005 Locally advanced breast cancer ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 65-69
105. 2005 Breast cancer: treatment of elderly patients and uncommon conditions ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 48-53
106. 2005 Management of regional nodes in breast cancer ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 42-47
107. 2005 Breast cancer: epidemiology, risk factors and genetics ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 24-29
108. 2005 Breast infection ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 19-23
109. 2005 Congenital problems and aberrations of normal development and involution ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 8-14
110. 2005 Symptoms, assessment and guidelines for referral ABC of Breast Diseases, 3rd Edition. Ed: Dixon JM. BMJ Books, Blackwell Publishing Ltd., London, 2005, pp 1-7.
111. 2005 Breast disease (benign) A New Aird’s Companion in Surgical Studies. 3rd Edition. Eds: Bernand KG, Young AE, Lucas J. Elsevier Ltd, Oxford 2005, pp 506-517
112. 2005 Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience Endocrine-Related Cancer 2005; 12: S119-S123.
113. 2005 Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours BMC Cancer 2005; 5: 113
114. 2005 A comprehensive approach for evaluating telemedicine-delivered multidisciplinary breast cancer meetings in Southern Scotland Journal of Telemedicine and Telecare 2005; 11 (suppl 1): 71-73
115. 2005 Breast cancer (non-metastatic). Clinical Evidence Concise 2005; 14: 555-560
116. 2005 Attitudes of breast cancer professionals to conventional and telemedicine-delivered multidisciplinary breast meetings Journal of Telemedicine and Telecare 2005; 11 (suppl 2: S2: 29-34
117. 2005 Aromatase inhibitors: cellular and molecular effects. Journal of Steroid Biochemistry and Molecular Biology 2005; 95: 83-89
118. 2005 Current management of breast cancer: a surgeon’s perspective MIMS Advances: Breast Cancer September 2005, 2-5
119. 2005 Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis Radiology 2005; 236: 779-788
120. 2005 Surgical issues surrounding the use of aromatase inhibitors Journal of Steroid Biochemistry and Molecular Biology 2005; 95: 97-103
121. 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the immediate preoperative anastrozole, tamoxifen or combined with tamoxifen (IMPACT) multicenter double-blind randomised trial. Journal of Clinical Oncology 2005; 23: 5108-5116
122. 2005 Short-term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence free survival Clinical Cancer Research 2005; 11: 951s-958s
123. 2005 Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARBIS). The Lancet 2005; 365: 1769-1778
124. 2005 Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists Journal of Clinical Oncology 2005; 23 (11): 2477-2492
125. 2005 Clinical studies with letrozole Aromatase Inhibitors. Ed: Furr BJA. Birkhauser, Basel. 2005, pp 65-94.
126. 2005 Neoadjuvant treatment Aromatase Inhibitors for the Treatment of Breast Cancer. Ed: Ellis MJ. CMP Healthcare Media, New York, 2005, pp 55-72
127. 2004 Breast cancer (non-metastatic). Clinical Evidence 2004; 12: 2449-2482
128. 2004 The scientific value of preoperative studies and how they can be used Breast Cancer Research and Treatment 2004; 87 (suppl 1): S19-S26
129. 2004 Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status European Journal of Cancer 2004; 40: 2742-2747
130. 2004 Role of endocrine therapy in the neoadjuvant surgical setting Annals of Surgical Oncology 2004; 11: 18s-23s
131. 2004 Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer European Journal of Cancer 2004; 40: 2403-2410
132. 2004 Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET) The Breast 2004; 13: 363-368
133. 2004 Neoadjuvant exemestane in the treatment of invasive breast carcinoma in postmenopausal women Case Studies in Breast Cancer 2004; 3: 3-6
134. 2004 Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node-negative status. Journal of Clinical Pathology 2004; 57: 845-848
135. 2004 Predictors of non-sentinel lymph node metastasis in breast cancer patients European Journal of Cancer 2004; 40: 1731-1737
136. 2004 A survey of surgical management of the axilla in UK breast cancer patients European Journal of Cancer 2004; 40: 1738-1742
137. 2004 Diagnostic delay in breast cancer British Journal of Surgery 2004; 91: 49-53
138. 2004 Exemestane and aromatase inhibitors in the management of advanced breast cancer Expert Opinion on Pharmacotherapy 2004; 5: 307-316
139. 2004 Breast cancer (non-metastatic). Clinical Evidence 2004; 11: 2300-2333.
140. 2004 Neoadjuvant therapy in postmenopausal women Advances in Endocrine Therapy of Breast Cancer. Eds: Ingle JN, Dowsett M. Marcel Dekker, New York, 2004
141. 2004 Management of disorders of the ductal system and infections. Diseases of the Breast, 3rd Edition. Eds: Harris JR, Lippman ME, Morrow M, Osborne CK. Lippincott Williams & Wilkins, Philaldephia, 2004, pp 47-56
142. 2003 Neoadjuvant use of anastrozole. History and Advancement of Anastrozole in the Treatment of Breast Cancer. Eds: Buzdar A, Baum M. Royal Society of Medicine 2003; pp 15-19.
143. 2003 Does local surgery have a role in the management of stage IV breast cancer? European Journal of Surgical Oncology 2003; 29: 17-19
144. 2003 Partial and total breast reconstruction. Journal of the Association of Chartered Physiotherapists in Women’s Health 2003; 92: 25-34.
145. 2003 Imprint cytology of axillary lymph nodes as an intraoperative diagnostic tool European Journal of Surgical Oncology 2003; 29: 224-228
146. 2003 Safety issues surrounding the use of aromatase inhibitors in breast cancer Expert Opinion. Drug Safety. 2003; 2(1): 73-86
147. 2003 Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation European Journal of Surgical Oncology 2003; 29: 475-479.
148. 2003 Biomarker status as a predictor of response to endocrine treatment in breast cancer Current Oncology 2003; 10 (suppl 1): S9-13
149. 2003 Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen European Journal of Cancer 2003; 39: 462-468
150. 2003 Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes Journal of Steroid Biochemistry & Molecular Biology 2003; 86: 295-299
151. 2003 An integrated view of aromatase and its inhibition Journal of Steroid Biochemistry and Molecular Biology 2003; 86: 413-421
152. 2003 Hormone replacement therapy and the breast Surgical Oncology 2003; 12: 251-263
153. 2003 Current limits of knowledge in adjuvant and neoadjuvant endocrine therapy of breast cancer: the need for more clinical research Surgical Oncology 2003; 12: 289-304
154. 2003 The pharmacology of letrozole Journal of Steroid Biochemistry and Molecular Biology 2003; 87: 34-45
155. 2003 Breast cancer (non-metastatic) Clinical Evidence 2003; 9: 1940-1970
156. 2003 Breast cancer (non-metastatic) Clinical Evidence 2003; 10: 376-379
157. 2002 Latissimus dorsi mini-flap: a technique for extending breast conservation The Breast 2002; 11: 58-65
158. 2002 Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen Anticancer Research 2002; 22: 2317-2320
159. 2002 Neoadjuvant endocrine therapy of breast cancer: a surgical perspective European Journal of Cancer 2002; 38: 2214-2221
160. 2002 Occult lymph node metastases in patients with ‘node negative’ breast carcinoma treated with conservative surgery and axillary node sample who subsequently developed axillary recurrence The Breast 2002; 11: 249-251.
161. 2002 MIB1 assessments in breast cancers The Breast 2002; 11: 252-256
162. 2002 The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). Journal of Experimental and Clinical Cancer Research 2002; 21: 107-114.
163. 2002 One stop clinics should not be abandoned BMJ 2002; 324: 507
164. 2002 Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. British Journal of Cancer 2002; 87: 334-338
165. 2002 Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer British Journal of Cancer 2002; 87: 950-955
166. 2002 Anti-tumour effects of letrozole Cancer Investigation 2002; 20: 15-21
167. 2002 Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index British Journal of Cancer 2002; 87: 8-14
168. 2002 Hormone replacement therapy: is it safe for breast cancer patients Medical Journal of Australia 2002; 175: 340-341
169. 2002 Breast cancer: non-metastatic Clinical Evidence 2002; 8: 1811-1839
170. 2002 Breast cancer: non-metastatic Clinical Evidence 2002; 7: 1603-1630
171. 2002 Breast Disease: Diagnostic Methods Surgical Practice Eds: Majid AA, Kingsnorth AN Greenwich Medical Media, London 2002; pp 379-385
172. 2002 Ductal carcinoma in situ: the Edinburgh experience. Ductal Carcinoma of the Breast, second edition Ed: Silverstein MJ. Lippincott Williams & Wilkins, Philadelphia 2002, pp 343-347
173. 2002 Adjuvant treatment in breast cancer Recent Advances in Surgery. Eds: Johnson C, Taylor I. Royal Society of Medicine Press, London, 2002, pp 191-204
174. 2002 Neoadjuvant therapy: prediction of response Endocrine Therapy in Breast Cancer. Eds: Miller WR, Ingle JN. Marcel Dekker Inc, New York, 2002; pp 223-229
175. 2002 Neoadjuvant therapy: surgical perspectives Endocrine Therapy in Breast Cancer. Eds: Miller WR, Ingle JN. Marcel Dekker Inc, New York, 2002; pp 197-212.
176. 2002 The Breast Principles and Practice of Surgery. Eds: Garden OJ, Forsythe JLR, Bradbury AW. Churchill Livingstone, Edinburgh, 2002, pp396-422
177. 2002 The value of adjuvant treatment in young women with breast cancer Drugs 2002; 62: 1-11
178. 2002 Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial: commentary Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial: commentary
179. 2002 Endocrine and clinical endpoints of exemestane as neoadjuvant therapy Cancer Control 2002; 9 (suppl): 9-15
180. 2002 Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment Future Drugs: Expert Review of Anticancer Therapy 2002; 2: 267-275
181. 2001 Local endocrine effects of aromatase inhibitors within the breast The Journal of Steroid Biochemistry & Molecular Biology 2001; 79: 93-102
182. 2001 Locally advanced breast cancer Breast Cancer: Diagnosis and Management. Ed: Dixon JM. Elsevier Science, Oxford, 2001; pp. 395-403
183. 2001 Breast cancer in elderly patients Breast Cancer: Diagnosis and Management. Ed: Dixon JM. Elsevier Science, Oxford, 2001; 369-375.
184. 2001 Neoadjuvant endocrine therapy Breast Cancer: Diagnosis and Management. Ed: Dixon JM. Elsevier Science, Oxford, 2001; pp. 305-309.
185. 2001 Breast reconstruction after mastectomy Breast Cancer: Diagnosis and Management. Ed: Dixon JM. Elsevier Science, Oxford, 2001; pp. 207-213
186. 2001 Hormones and Chemotherapy A Companion to Specialist Surgical Practice: Breast and Endocrine Surgery, 2nd edition Ed: Farndon JR. WB Saunders, London 2001, pp 107-146
187. 2001 Is lactation mastitis and shooting breast pain experienced by women during lactation caused by Candida albicans? The Breast 2001; 11: 88-90
188. 2001 Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy Journal of Steroid Biochemistry & Molecular Biology 2001; 79: 103-107
189. 2001 Hormone replacement therapy and the breast BMJ 2001; 323: 1381-1382
190. 2001 Letrozole as primary medical therapy for locally advanced and large operable breast cancer Breast Cancer Research and Treatment 2001; 66 (3): 191-199
191. 2001 Clinical update: fibroadenoma of the breast Medical Journal of Australia 2001; 174: 185-18
192. 2001 The truth about breast cancer Women’s Health Letter 2001; 10, 4-6
193. 2000 Breast cancer: detection and management The Practitioner 2000; 244: 884-898
194. 2000 Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study Magnetic Resonance Imaging 2000; 18: 765-776
195. 2000 Charity spice BMJ 2000; 321: 1479
196. 2000 Treating young patients with breast cancer BMJ 2000; 320: 457-458
197. 2000 Localization of breast lesions shown only on MRI – a review for the UK study of MRI Screening for breast cancer British Journal of Radiology 2000; 73: 123-132
198. 2000 Rationale for a national multi-centre study of magnetic resonance imaging (MRI) screening in women at genetic risk of breast cancer. The Breast 2000; 9: 72-77.
199. 2000 Protocol for a national multi-centre study of magnetic resonance imaging (MRI) screening in women at genetic risk of breast cancer The Breast 2000; 9: 78-82
200. 2000 Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation. The Breast 2000; 9: 156-157
201. 2000 The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study Clinical Cancer Research 2000; 6: 2229-2235
202. 2000 Estrone and estradiol metabolims in vivo in human breast cysts Steroids 2000; 65: 883-888
203. 2000 Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. European Journal of Cancer 2000; 36: 845-851
204. 2000 Antiaromatase agents: preclinical data and neoadjuvant therapy Clin Breast Cancer 2000; Suppl 1: S9-S14
205. 2000 Neoadjuvant endocrine therapy Aromatase Inhibition and Breast Cancer. Eds: Miller WR, Santen RJ. Marcel Dekker, Inc, New York, 2000, pp103-116
206. 2000 Induction and suppression of aromatase by inhibitors. Aromatase Inhibition and Breast Cancer. Eds: Miller WR, Santen RJ. Marcel Dekker, Inc, New York, 2000, pp 213-226
207. 2000 Benign breast disease (chapter 5.1) Textbook of Surgery: Breast/Endocrine Section. Ed: Williams RCN. Harcourt Health Sciences, London 2000
208. 2000 Breast cancer: epidemiology (chapter 5.2) Textbook of Surgery: Breast/Endocrine Section. Ed: Williams RCN. Harcourt Health Sciences, London 2000
209. 2000 Recurrent periareolar sepsis (chapter 5.11.1) Textbook of Surgery: Breast/Endocrine Section. Ed: Williams RCN. Harcourt Health Sciences, London 2000
210. 2000 Blood-stained discharge from a single nipple duct (chapter 5.11.2) Textbook of Surgery: Breast/Endocrine Section. Ed: Williams RCN. Harcourt Health Sciences, London 2000
211. 2000 Mass in a young woman: observe or excise? (Chapter 5.11.3) Textbook of Surgery: Breast/Endocrine Section. Ed: Williams RCN. Harcourt Health Sciences, London 2000
212. 2000 Symptoms, assessment and guidelines for referral ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 1-9
213. 2000 Congenital problems and aberrations of normal development and involution. ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 10-15
214. 2000 Breast infection ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 21-25
215. 2000 Breast cancer – epidemiology, risk factors and genetics ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 26-32
216. 2000 Management of regional nodes in breast cancer ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 44-49
217. 2000 Breast cancer: treatment of elderly patients and uncommon conditions ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 50-54
218. 2000 Locally advanced breast cancer. ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 61-64
219. 2000 Metastatic breast cancer ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 65-71
220. 2000 Clinical trials and management of breast cancer ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 78-84
221. 2000 Carcinoma in situ ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 90-96
222. 2000 Breast reconstruction ABC of Breast Diseases, 2nd Edition Ed: Dixon JM. BMJ Books, London 2000, pp 97-103
223. 2000 Data on effect of HRT on breast cancer conflict with other data BMJ 2000; 321: 179
224. 2000 Antiproliferative effect of idoxifene in a placebo-controlled trial in primary human breast cancer. Clinical Cancer Research 2000; 6: 2260-2267
225. 2000 Ductal carcinoma in situ revisited. The Breast 2000; 9: 175-176
226. 2000 Concentrations of tamoxifen and its major metabolites in hormone sensitive breast tumours British Journal of Cancer 2000; 82: 1629-1635.
227. 2000 Gynaecomastia: when is action required? Gynaecomastia: when is action required?
228. 2000 ABC of Breast Diseases: Breast cancer – epidemiology, risk factors and genetics BMJ 2000; 321: 624-628
229. 1999 Neoadjuvant endocrine treatment: the Edinburgh experience. Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects. European School of Oncology Scientific Updates, 4. Eds: Veronesi U, Aapro MS Elsevier Science, The Netherlands, 1999, pp 89-99
230. 1999 Who should provide the diagnostic service? Key Advances in the Effective Management of Breast Cancer. Eds: Baum M, Spittle M. Royal Society of Medicine Press, London 1999; pp 11-13
231. 1999 Management of disorders of the ductal system and infections Diseases of the Breast: 2nd Edition Eds: Harris J, Lippman ME, Morrow M and Osborne CK Lippincott Williams and Wilkins, Philadelphia 1999; pp 47-55
232. 1999 Managing breast pain The Practitioner 1999; 243: 484-491
233. 1999 Risk of breast cancer in women with palpable breast cysts The Lancet 1999; 353: 1742-1745
234. 1999 Accuracy of intraoperative frozen-section analysis of axillary nodes British Journal of Surgery 1999; 86: 392-395
235. 1999 Palpable cysts were associated with an increased risk for breast cancer. Evidence Based Medicine 1999; 4: 192
236. 1999 Radiotherapy and tamoxifen after surgery improved local control and survival in breast cancer. Evidence Based Medicine 1999; 4: 183
237. 1999 An investigation of endometrial abnormalities in asymptomatic women on tamoxifen and an evaluation of the role of endometrial screening Journal of Clinical Oncology 1999; 17 (7): 2050-2054
238. 1999 Lessons from the use of aromatase inhibitors in the neoadjuvant setting Endocrine Related Cancer 1999; 6: 227-230
239. 1999 Preservation of the intercostobrachial nerve during axillary node clearance for breast cancer reduced sensory deficits Evidence Based Medicine 1999; 4: 85
240. 1998 Benign breast disease The New Aird’s Companion to Surgical Studies, 2nd Edition Eds: Bernand KG and Young AE. Churchill Livingstone, Edinburgh 1998, pp 631-663
241. 1998 Ductal carcinoma in situ of the breast (editorial The Breast 1998; 7: 239-242.
242. 1998 Total duct excision The Breast 1998; 7: 216-219
243. 1998 Hormone treatments in breast cancer Breast News 1998
244. 1998 Sentinel node biopsy in breast cancer (editorial) British Medical Journal 1998; 317: 295-296
245. 1998 Clinical importance of intratumoural aromatase Breast Cancer Research and Treatment 1998; 49 (suppl 1): S27-32
246. 1998 Breast disease GP 1998; 14 August: 32
247. 1998 Benign Breast Disease (Invited Comment). Crucial Controversies in Surgery. Eds: Schein M, Wise L. Karger Landes Systems, Basel 1998, pp 106-112
248. 1998 Angiogenesis and breast cancer The Breast 1998; 7: 299-307
249. 1998 Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast The Breast 1998; 7: 273-276
250. 1998 Patterns of recurrence of breast cancer following breast-conserving treatment The Breast 1998; 7: 106-107
251. 1998 Morbidity related to intercostobrachial nerve damage following axillary surgery for breast cancer. The Breast 1998; 7: 209-212
252. 1998 Axillary node sampling in breast cancer: an assessment of its efficacy The Breast 1998; 7: 206-208
253. 1998 Periductal mastitis and duct ectasia: an update The Breast 1998; 7: 128-130
254. 1997 Hormones and Chemotherapy. A Companion to Specialist Surgical Practice: Breast and Endocrine Surgery Ed: Farndon JR. WB Saunders, London 1997, pp 275-308
255. 1997 Ductal Carcinoma in situ: the Edinburgh experience Ductal carcinoma in situ: a diagnostic and therapeutic dilemma. Ed: Silverstein MJ. Williams and Wilkins, USA 1997, pp 379-384
256. 1997 Expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Research and Treatment 1997; 44: 123-133
257. 1997 Uptake of dehydroepiandrostene sulphate into human breast cyst fluids The Breast 1997; 6: 12-16
258. 1997 Regulation of aromatase activity within the breast Pulse 1997; April: 100
259. 1997 Pleurocutaneous fistula as a complication of radiation treatment in locally advanced breast cancer. Journal of the Royal College of Surgeons of Edinburgh 1997; 42: 138-139
260. 1997 Ovarian ablation in early breast cancer: overview of the randomised trials Evidence Based Medicine 1997; 2: 75
261. 1996 Removing bias in surgical trials (editorial) British Medical Journal 1997; 314: 916-917
262. 1996 Breast conserving surgery plus radiation therapy was as effective as mastectomy Evidence Based Medicine 1996; 1: 49
263. 1996 Assessment of the acceptability of conservative management of fibroadenoma of the breast British Journal of Surgery 1996; 83: 264-265
264. 1996 Solid-phase extraction and high performance liquid chromatography determination of tamoxifen and its major metabolites in plasma Journal of Chromatography B: Biomedical Applications 1996; 678: 317-323
265. 1996 Periductal mastitis and duct ectasia: different conditions with different aetiologies British Journal of Surgery 1996; 83: 820-822
266. 1996 Factors affecting outcome of patients with impalpable breast cancers detected by breast screening British Journal of Surgery 1996; 83: 997-1001
267. 1996 Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy British Journal of Cancer 1996; 74: 474-478
268. 1996 Prospective evaluation of prognostic factors in operable breast cancer. British Journal of Cancer 1996; 74: 1469-1478
269. 1996 Different local therapies for early breast cancer do not affect overall survival Evidence Based Medicine 1996; 1: 118
270. 1996 Breast Color Atlas of Surgical Diagnosis. Eds: Greig JD, Garden OJ. Mosby-Wolfe, London 1996, pp 24-36
271. 1995 Transforming growth factor ß1 is unlikely to mediate p53 abnormalities in breast cancer British Journal of Surgery 1995; 82: 210-211
272. 1995 Surgical morbidity following primary systemic therapy for breast cancer: a randomised study British Journal of Surgery 1995; 82: 79-81
273. 1995 ABC of breast diseases: management of carcinoma in situ and patients at "high risk" of subsequent breast cancer British Medical Journal 1995; 310: 39-42
274. 1995 ABC of breast diseases: breast reconstruction following surgery for breast cancer British Medical Journal 1995; 310: 117-121
275. 1995 Common surgical ailments: breast cysts Current Practice in Surgery 1995; 7: 118-122
276. 1995 Surgery and radiotherapy for early breast cancer (editorial) British Medical Journal 1995; 311: 1515-1516
277. 1995 Role of axillary dissection in women with early breast cancer Role of axillary dissection in women with early breast cancer
278. 1995 Breast reconstruction (leading article). British Journal of Surgery 1995; 82: 865-866
279. 1994 Smoking in patients with periductal mastitis and duct ectasia Recent Developments in the Study of Benign Breast Disease. The Proceedings of the 5th International Benign Breast Disease Symposium Ed: Mansel RE Parthenon Publishing, London 1994; pp 215-219
280. 1994 Effects of spironolactone, danazol and Efamast on the uptake of tritiated dehydroepiandrosterone sulphate into human breast cyst fluid Recent Developments in the Study of Benign Breast Disease. The Proceedings of the 5th International Benign Breast Disease Symposium Ed: Mansel RE Parthenon Publishing, London 1994; pp 265-270
281. 1994 Natural history of fibroadenoma of the breast Recent Developments in the Study of Benign Breast Disease. The Proceedings of the 5th International Benign Breast Disease Symposium Ed: Mansel RE Parthenon Publishing, London 1994; pp 75-81
282. 1994 Diagnosis of benign lesions in a modern breast clinic Recent Developments in the Study of Benign Breast Disease. The Proceedings of the 5th International Benign Breast Disease Symposium Ed: Mansel RE Parthenon Publishing, London 1994; pp 33-38
283. 1994 ABC of breast diseases: prognostic factors British Medical Journal 1994; 309:1573-1576
284. 1994 ABC of breast diseases: metastatic breast cancer British Medical Journal 1994; 309: 1501-1504
285. 1994 ABC of breast diseases: locally advanced breast cancer British Medical Journal 1994; 309: 1431-1433
286. 1994 ABC of breast diseases: role of systemic therapy in primary operable breast cancer British Medical Journal 1994; 309: 1363-1366.
287. 1994 ABC of breast diseases: breast cancer: treatment of elderly patients and uncommon conditions British Medical Journal 1994; 309: 1292-1295
288. 1994 ABC of breast diseases: management of regional nodes in breast cancer British Medical Journal 1994; 309: 1222-1225
289. 1994 ABC of breast diseases: breast cancer. British Medical Journal 1994; 309: 1150-1153
290. 1994 ABC of breast diseases: screening for breast cancer British Medical Journal 1994; 309: 1076-1079
291. 1994 ABC of breast diseases: breast cancer - epidemiology, risk factors and genetics British Medical Journal 1994; 309: 1003-1006
292. 1994 ABC of breast diseases: breast infection British Medical Journal 1994; 309: 946-949
293. 1994 ABC of breast diseases: congenital problems and aberrations of normal development and involution. British Medical Journal 1994; 309: 797-800
294. 1994 ABC of breast diseases: symptoms, assessment and guidelines for referral. British Medical Journal 1994; 309: 722-726
295. 1994 Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21.
296. 1994 Consensus document on staging for breast cancer The Breast 1994; 3: 238-240
297. 1994 Colour Doppler studies of axillary node metastases in breast carcinoma Clinical Radiology 1994; 49: 189-191.
298. 1994 P-glycoprotein and resistance to tamoxifen Lancet 1994; 343: 1047-1048
299. 1994 Expression of transforming growth factor beta mRNA isoforms in human breast cancer British Journal of Cancer 1994; 69: 1006-1009
300. 1993 Screening for breast cancer British Journal of Surgery 1993; 80: 141-142.
301. 1993 Wisdom of cancer screening II Surgery 1993; 11: 343-344
302. 1993 Infusional 5 fluorouracil given as a single agent in relapsed breast cancer: its activity and toxicity. The Breast 1994; 3: 87-89.
303. 1993 Breast conservation surgery Recent Advances in Surgery 1993; 16: 43-61.
304. 1993 Specimen-orientated radiography helps define excision margins of malignant lesions detected by breast screening British Journal of Surgery 1993; 80: 1001-1002
305. 1993 Importance of interpectoral nodes in breast cancer European Journal of Cancer 1993; 29: 334-336
306. 1993 Indications for and techniques of breast biopsy Current Practice in Surgery 1993; 5: 142-148
307. 1992 Morbidity after breast biopsy for benign disease in a screened population Lancet 1992; 339: 128
308. 1992 Management of early breast cancer British Medical Journal 1992; 305: 114-115
309. 1992 Aspiration cytology of the breast with immediate reporting: initial experience with 1000 patients in a district general hospita Journal of the Royal College of Surgeons of Edinburgh 1992; 37: 207
310. 1992 Use of a breast template: an aid for orientation of breast biopsy specimens. Annals of the Royal College of Surgeons of England 1992; 74: 150
311. 1992 Morbidity after breast biopsy for benign disease in a screened population Lancet 1992; 339: 128
312. 1992 Fine needle aspiration cytology: How I do it. Recent Developments in the Study of Benign Breast Disease: Proceedings of the 4th International Benign Breast Disease Symposium. Ed: Mansel RE Parthenon Publishing Group, New Jersey 1992; pp 197-201
313. 1992 Breast surgery Infection in Surgical Practice. Ed: Taylor I Oxford University Press, Oxford 1992; pp 187-196
314. 1992 Benign breast disease A New Airds Companion to Surgical Studies. Eds: Bernand and Young. Churchill Livingstone, Edinburgh 1992; pp 811-826
315. 1992 Nomenclature of benign breast disorders: Report of a working party on the rationalisation of concepts and terminology of benign breast conditions The Breast 1992; 1: 15-17.
316. 1992 Marking of excision specimens in patients undergoing stereotactic wide local excision for breast cancer British Journal of Surgery 1992; 79: 55.
317. 1992 Outpatient treatment of non-lactating breast abscesses British Journal of Surgery 1992; 79: 56-57
318. 1992 PDS IIR (Polydioxanone) is the monofilament suture of choice for subcuticular wound closure following breast biopsy Journal of the Royal College of Surgeons of Edinburgh 1992; 37: 94-96
319. 1992 Colour Doppler studies of axillary nodes in patients with breast cancer British Journal of Radiology 1992; 65: 142
320. 1992 Treatment of elderly patients with breast cancer British Medical Journal 1992; 304: 996-997
321. 1992 Aspiration cytology of the breast with immediate reporting: initial experience with 1000 patients in a district general hospital Aspiration cytology of the breast with immediate reporting: initial experience with 1000 patients in a district general hospital
322. 1992 Familial breast cancer Familial breast cancer
323. 1992 Advanced breast cancer Surgery 1992; 10: 24
324. 1992 Quadrantectomy for early breast cancer British Journal of Surgery 1992; 79: 184
325. 1991 Axillary dissection in primary breast cancer British Medical Journal 1991; 302: 590
326. 1991 Pneumothorax after fine needle aspiration of the breast British Medical Journal 1991; 302: 924
327. 1991 Management of mammillary fistulae Journal of the Royal College of Surgeons of Edinburgh 1991; 37: 284.
328. 1991 Breast lumps: when there is no need to worry Family Circle Magazine 1991; 82
329. 1991 Immediate reporting of fine needle aspiration cytology of breast lesions British Medical Journal 1991; 302: 428-429
330. 1991 Wound compression pads are of no value after local anaesthetic breast biopsy Annals of the Royal College of Surgeons of England 1991; 73: 303-304
331. 1991 Effective surgical treatment for mammillary fistula British Journal of Surgery 1991; 78: 1185-1186
332. 1991 Colour flow Doppler studies of benign and malignant breast lesions British Journal of Surgery 1991; 78: 259-260
333. 1991 Mammography in the management of patients with small breast cancers British Journal of Surgery 1991; 78: 218-219
334. 1991 Cystic disease and fibroadenoma of the breast: natural history and relation to breast cancer risk. British Medical Bulletin. Breast Cancer - New Approaches. Eds: Stewart, Anderson and Forrest. Churchill Livingstone, Edinburgh 1991; pp 258-271
335. 1991 The axilla: not a no go area Lancet 1991; i: 487
336. 1991 Diagnosing breast carcinoma in young women British Medical Journal 1991; 302: 911
337. 1990 The H-ras oncogene product p21 and prognosis in human breast cancer Breast Cancer Research and Treatment 1990; 17: 161-169
338. 1990 Cystic disease of the breast Benign Breast Disease Eds: Taylor and Smallwood. Edward Arnold 1990; pp 66-84
339. 1990 Cyclic AMP binding protein and prognosis in breast cancer British Journal of Cancer 1990; 61: 263-266
340. 1989 Breast abscesses Breast abscesses
341. 1989 Periductal mastitis/duct ectasia World Journal of Surgery 1989; 13: 715-720.
342. 1989 Periductal mastitis - aetiology and management British Journal of Clinical Practice 1989; 43 (suppl 68): 76-80
343. 1989 Pathogenesis of cystic disease British Journal of Clinical Practice 1989; 43 (suppl 68): 90-93.
344. 1988 Repeated aspiration of breast abscesses in lactating women British Medical Journal 1988; 297: 1517-1518
345. 1988 Fine needle aspiration cytology of breast masses Annals of the Royal College of Surgeons of England 1988; 70: 184
346. 1988 Treatment of periareolar inflammation associated with periductal mastitis using Metronidazole and Flucloxacillin: a preliminary report British Journal of Clinical Practice 1988; 42: 78-80
347. 1988 Wound infection after breast biopsy British Journal of Surgery 1988; 75: 918-919
348. 1987 Primary lymphoma of the breast British Journal of Surgery 1987; 74: 214-217
349. 1987 Reduction in the biopsy rate in benign breast disease using fine needle aspiration cytology with immediate reporting British Journal of Surgery 1987; 74: 1014-1016
350. 1987 Fine needle aspiration cytology with immediate reporting in the outpatient diagnosis of breast disease Annals of the Royal College of Surgeons of England 1987: 6: 280-282.
351. 1987 The role of FNA cytology in breast cancer screening Journal of Clinical Pathology 1987; 7: 705-709
352. 1987 Prognostic significance of oestrogen and progestogen receptor activities in breast cancer British Journal of Surgery 1987; 74: 1009-1013
353. 1987 Mammillary fistula British Journal of Surgery 1987; 74: 466-468
354. 1986 Mammillary fistula Lancet 1986; ii: 1045
355. 1986 Infiltrating lobular carcinoma of the breast British Medical Journal 1986; 292: 60.
356. 1986 Frozen section of trucut biopsies versus cytology British Journal of Surgery 1986; 73: 324-325.
357. 1986 Hormonal correlates of apocrine secretion in the breast Annals of New York Academy of Science 1986; 464: 275-287
358. 1986 Fine needle aspiration of breast cancer: relationship of clinical factors to cytology results in 689 primary malignancies Cancer 1986; 58: 1493-1498
359. 1985 Long term survivors from breast cancer British Journal of Surgery 1985; 72: 445-448
360. 1985 Refilling of breast cysts as an indication for breast biopsy Lancet 1985; ii: 608
361. 1985 Natural history of cystic disease: importance of cyst type British Journal of Surgery 1985; 72: 190-192
362. 1985 Androgen metabolism and apocrine differentiation in human breast cancer Breast Cancer Research and Treatment 1985; 5: 67-73.
363. 1985 Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity European Journal of Cancer 1985; 21: 539-542
364. 1985 An analysis of the content and morphology of human breast microcysts European Journal of Surgical Oncology 1985; 11: 151-154
365. 1985 The relationship of cyst type to risk factors for breast cancer and subsequent development of breast cancer in patients with breast cystic disease European Journal of Cancer and Clinical Oncology 1985; 21: 1047- 1050.
366. 1985 Are the lesions of duct ectasia sterile? British Journal of Surgery 1985; 72: 844-845
367. 1984 Human breast cystic disease Breast News 1984; 1: 608
368. 1984 Fine needle aspiration cytology in relationship to clinical examination and mammography in the diagnosis of a solid breast mass British Journal of Surgery 1984; 71: 593-596
369. 1984 Polyamines in breast cancer British Journal of Surgery 1984; 71: 352-356
370. 1984 pH of human breast cyst fluids Clinical Oncology 1984; 10: 221-224
371. 1984 Clinical assessment of tumour size in primary breast carcinoma Clinical Oncology 1984; 10: 117-122.
372. 1984 Which patients are cured of breast cancer British Medical Journal 1984; 71: 1007
373. 1984 Mammary duct ectasia - studies of factors involved in its aetiology and pathogenesis Breast News 1984; 4: 1-5
374. 1983 Classification of human breast cysts according to electrolyte and androgen conjugate composition. Clinical Oncology 1983; 9: 227-232
375. 1983 The clinical syndrome of mammary duct ectasia British Journal of Surgery 1983; 70: 57-58.
376. 1983 Adrenaline in breast biopsy Wrexham Medical Journal 1983; 11: 4-10.
377. 1983 Invasive cribriform carcinoma of the breast Histopathology 1983; 7: 525-536
378. 1983 Mammary duct ectasia British Journal of Surgery 1983; 70: 601-603
379. 1983 The morphological basis of human breast cyst populations. British Journal of Surgery 1983; 70: 604-606
380. 1983 Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease British Journal of Surgery 1983; 70: 513-516
381. 1983 The advantage of adrenaline in local and general anaesthetic breast biopsy Journal of the Royal College of Surgeons of Edinburgh 1983; 28: 292-294
382. 1983 Fine needle aspiration of the breast: the importance of the aspirator Lancet 1983; ii: 564
383. 1982 Infiltrating lobular carcinoma of the breast Histopathology 1982; 6: 149-161
384. 1981 Oestrogen receptor concentration in primary breast cancer and axillary node metastases Breast Cancer Research and Treatment 1981; 1: 245-251


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.